Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD – Get Free Report) have been given an average recommendation of “Hold” by the five analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $4.5833.
Several analysts have commented on HYPD shares. Zacks Research upgraded shares of Hyperion DeFi to a “hold” rating in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Wednesday, October 8th. Cantor Fitzgerald assumed coverage on Hyperion DeFi in a research report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price target on the stock. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Chardan Capital set a $7.75 target price on shares of Hyperion DeFi and gave the company a “buy” rating in a report on Wednesday, December 24th.
Get Our Latest Stock Report on HYPD
Insider Buying and Selling
Hyperion DeFi Stock Performance
NASDAQ:HYPD opened at $3.37 on Wednesday. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11. The firm’s fifty day simple moving average is $4.79 and its 200 day simple moving average is $7.60. The stock has a market cap of $27.54 million, a P/E ratio of -0.83 and a beta of 2.80. Hyperion DeFi has a twelve month low of $0.85 and a twelve month high of $17.99.
Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last posted its earnings results on Friday, November 14th. The company reported $0.05 EPS for the quarter. The firm had revenue of $0.36 million during the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 119.59%. As a group, research analysts predict that Hyperion DeFi will post -41.6 EPS for the current year.
About Hyperion DeFi
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Further Reading
- Five stocks we like better than Hyperion DeFi
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
